Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pitavastatin Sodium

FDA-approved product (tablet, oral), marketed as Livalo, Pitavastatin Calcium, Zypitamag and 1 more.

Registered studies
18
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Pitavastatin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Abnormal circulating lipid concentration
  • Cardiovascular disease
  • Familial hypercholesterolemia
  • Hypercholesterolemia
  • Hyperlipidemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hmg coa reductase inhibitors
FDA pharmacologic class
HMG-CoA Reductase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae19.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

18registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pitavastatin Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pitavastatin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of LY3015014 in Participants With High Cholesterol

    NCT01890967 · start 2013-06

    Registered record
    Registry ID
    NCT01890967
    Conditions
    Hypercholesterolemia
    Interventions
    LY3015014; Placebo; Statin; Ezetimibe
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-06
    Completion
    2014-06
    Enrolment
    527

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolemia
    InterventionLY3015014; Placebo; Statin; Ezetimibe
    PhasePhase 2
    Registry statusCompleted

  • A Study Comparing CoQ10 Levels While Taking 3 Different Statins

    NCT01660191 · start 2011-12

    Registered record
    Registry ID
    NCT01660191
    Conditions
    Hypercholesterolemia
    Interventions
    Pitavastin 4mg; Atorvastatin 20mg; Rosuvastatin 5mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-12
    Completion
    2013-10
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolemia
    InterventionPitavastin 4mg; Atorvastatin 20mg; Rosuvastatin 5mg
    PhasePhase 4
    Registry statusCompleted

  • Drug-Drug Interaction Study to Assess the Effects of Steady State Pitavastatin 4 mg or Rosuvastatin 40 mg on Steady-State Warfarin in Healthy Adult Volunteers

    NCT01178853 · start 2010-07

    Registered record
    Registry ID
    NCT01178853
    Conditions
    Healthy
    Interventions
    Warfarin; Warfarin 5mg + Rosuvastatin 40 mg once daily (QD); Warfarin 5 mg + Pitavastatin 4mg once daily (QD)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-07
    Completion
    2011-04
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionWarfarin; Warfarin 5mg + Rosuvastatin 40 mg once daily (QD); Warfarin 5 mg + Pitavastatin 4mg once daily (QD)
    PhasePhase 4
    Registry statusCompleted